<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04836481</url>
  </required_header>
  <id_info>
    <org_study_id>2020-0744</org_study_id>
    <nct_id>NCT04836481</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetic Analysis of Levetiracetam Prophylaxis in Critically Ill Patients With Severe Traumatic Brain Injury</brief_title>
  <official_title>A Pharmacokinetic Analysis of Levetiracetam Prophylaxis in Critically Ill Patients With Severe Traumatic Brain Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American College of Clinical Pharmacy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cincinnati</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims is to describe the pharmacokinetic properties of levetiracetam through&#xD;
      measurement of serum concentrations in critically ill, severe traumatic brain injury&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Levetiracetam (LEV) is widely used for the prevention and treatment of seizures given its&#xD;
      favorable pharmacokinetic profile. A strong correlation between serum concentrations and&#xD;
      clinical efficacy has yet to be established; however, a target of 6-20 g/mL is recommended.&#xD;
      Limited evidence exists supporting an optimal dosing strategy to achieve these target&#xD;
      concentrations in neurocritically ill patients. Previous pharmacokinetic models suggest LEV&#xD;
      1000 mg every 8 hours achieves the highest proportion of therapeutic serum concentrations,&#xD;
      but this dosing strategy has not been clinically studied in neurocritically ill patients.&#xD;
      Additionally, only one phase two study has evaluated LEV pharmacokinetics in severe traumatic&#xD;
      brain injury (TBI).&#xD;
&#xD;
      The aim of this study is to describe the pharmacokinetic properties of LEV through&#xD;
      measurement of serum concentrations in critically ill, severe TBI patients. Secondarily, this&#xD;
      study aims to develop a population pharmacokinetic model aimed at characterizing LEV dose&#xD;
      optimization in severe TBI. An exploratory aim is to evaluate LEV pharmacodynamics in severe&#xD;
      TBI patients through evaluation of physiologic, electrophysiologic and biochemical changes&#xD;
      using multimodal monitoring or surface electroencephalogram (EEG), as available. A subgroup&#xD;
      analysis will evaluate LEV pharmacokinetics in severe TBI patients with augmented renal&#xD;
      clearance (ARC).&#xD;
&#xD;
      This prospective, single-center pharmacokinetic and pharmacodynamic study will include&#xD;
      critically ill patients receiving intravenous LEV for seizure prophylaxis following severe&#xD;
      TBI. Patients with severe TBI qualifying for multimodal monitoring will receive LEV 1000 mg&#xD;
      every 8 hours (LEV8) per institutional practice. All other severe TBI patients will receive&#xD;
      LEV 1000 mg every 12 hours (LEV12) according to institution practice. Patients with renal&#xD;
      dysfunction (creatinine clearance &lt; 50 mL/min) will be excluded. All patients will have five&#xD;
      serum samples collected following the sixth or greater consecutive dose. Patients receiving&#xD;
      LEV8 will have samples collected at 0.5, 1, 4, 6, and 8 hours. Patients receiving LEV12 will&#xD;
      have samples collected at 0.5, 1, 4, 8, and 12 hours. Serum concentrations will be analyzed&#xD;
      with pharmacokinetic modeling and Monte Carlo simulations. LEV pharmacodynamics will be&#xD;
      evaluated in patients receiving multimodal monitoring or surface EEG, as available. Analysis&#xD;
      of ARC will include patients with Augmented Renal Clearance in Trauma Intensive Care (ARTIC)&#xD;
      score &gt;6 during sampling.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Levetiracetam Concentration 1</measure>
    <time_frame>Hour 0.5</time_frame>
    <description>Serum levetiracetam concentration collected at 0.5 hours after target dose for sampling</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Levetiracetam Concentration 2</measure>
    <time_frame>Hour 1</time_frame>
    <description>Serum levetiracetam concentration collected at hour 1 after target dose for sampling</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Levetiracetam Concentration 3</measure>
    <time_frame>Hour 4</time_frame>
    <description>Serum levetiracetam concentration collected at hour 4 after target dose for sampling</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Levetiracetam Concentration 4</measure>
    <time_frame>Hour 6-8</time_frame>
    <description>Serum levetiracetam concentration collected at hour 6 (patients receiving every 8 hour levetiracetam) or hour 8 (patients receiving every 12 hour levetiracetam)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Levetiracetam Concentration 5</measure>
    <time_frame>Hour 8-12</time_frame>
    <description>Serum levetiracetam concentration collected at hour 8 (patients receiving every 8 hour levetiracetam) or hour 12 (patients receiving every 12 hour levetiracetam)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intracranial Pressure</measure>
    <time_frame>Baseline to Day 7</time_frame>
    <description>Collected at baseline and at each time of serum sample collection for pharmacodynamic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral Perfusion Pressure</measure>
    <time_frame>Baseline to Day 7</time_frame>
    <description>Collected at baseline and at each time of serum sample collection for pharmacodynamic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pressure Reactivity Index</measure>
    <time_frame>Baseline to Day 7</time_frame>
    <description>Collected at baseline and at each time of serum sample collection for pharmacodynamic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral Blood Flow</measure>
    <time_frame>Baseline to Day 7</time_frame>
    <description>Collected at baseline and at each time of serum sample collection for pharmacodynamic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral Microdialysis Glucose Concentration</measure>
    <time_frame>Baseline to Day 7</time_frame>
    <description>Collected at baseline and at each time of serum sample collection for pharmacodynamic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral Microdialysis Pyruvate Concentration</measure>
    <time_frame>Baseline to Day 7</time_frame>
    <description>Collected at baseline and at each time of serum sample collection for pharmacodynamic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral Microdialysis Lactate Concentration</measure>
    <time_frame>Baseline to Day 7</time_frame>
    <description>Collected at baseline and at each time of serum sample collection for pharmacodynamic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral Microdialysis Glutamate Concentration</measure>
    <time_frame>Baseline to Day 7</time_frame>
    <description>Collected at baseline and at each time of serum sample collection for pharmacodynamic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral Microdialysis Glycerol Concentration</measure>
    <time_frame>Baseline to Day 7</time_frame>
    <description>Collected at baseline and at each time of serum sample collection for pharmacodynamic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ARTIC Score</measure>
    <time_frame>Hour 0.5 (Collected at time of first serum sample collection)</time_frame>
    <description>Calculated ARTIC score</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>LEV8</arm_group_label>
    <description>Levetiracetam 1000 mg every 8 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LEV12</arm_group_label>
    <description>Levetiracetam 1000 mg every 12 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Serum Sample Collection</intervention_name>
    <description>Each patient will have 5 serum samples collected for analysis after a minimum six consecutive doses. Patients receiving LEV8 will have sampled collected at hours 0.5, 1, 4, 6, and 8. Patients receiving LEV12 will have sampled collected at hours 0.5, 1, 4, 8, and 12.</description>
    <arm_group_label>LEV12</arm_group_label>
    <arm_group_label>LEV8</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The target population for this study will be patients with severe traumatic brain injury,&#xD;
        defined as a post-resuscitation GCS 3-8 with or without CT abnormalities who are receiving&#xD;
        intravenous levetiracetam 1000 mg every 8 or every 12 hours for seizure prophylaxis.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Admitted to the neurosurgical intensive care unit or surgical intensive care unit&#xD;
             following severe traumatic brain injury (post-resuscitation GCS 3-8 with or without CT&#xD;
             abnormalities)&#xD;
&#xD;
          -  Receiving intravenous levetiracetam for seizure prophylaxis at a dose of 1000 mg every&#xD;
             12 hours or 1000 mg every 8 hours at time of enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known history of epilepsy or seizure disorder&#xD;
&#xD;
          -  Taking antiseizure medication prior to admission&#xD;
&#xD;
          -  Taking medication with known effect on levetiracetam pharmacokinetics including&#xD;
             carbamazepine, phenytoin, oxcarbazepine, mefloquine, methotrexate, mianserin, or&#xD;
             orlistat&#xD;
&#xD;
          -  Weight &lt; 50 kg&#xD;
&#xD;
          -  Anticipated survival &lt;72 hours from injury, as deemed by the primary neurosurgical&#xD;
             provider&#xD;
&#xD;
          -  Acute Kidney Injury (Scr rise &gt; 0.3 mg/dL from baseline) or creatinine clearance &lt;50&#xD;
             mL/min at time of enrollment&#xD;
&#xD;
          -  Prisoners&#xD;
&#xD;
          -  Pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah Schuman Harlan, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shaun Keegan, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carolyn Philpott, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sarah Schuman Harlan, PharmD</last_name>
    <phone>513-584-1070</phone>
    <email>sarah.schuman@uchealth.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shaun Keegan, PharmD</last_name>
    <phone>513-584-7675</phone>
    <email>shaun.keegan@uchealth.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaun Keegan, PharmD</last_name>
      <phone>513-584-7675</phone>
      <email>shaun.keegan@uchealth.com</email>
    </contact>
    <contact_backup>
      <last_name>Carolyn Philpott, PharmD</last_name>
      <phone>513-584-8371</phone>
      <email>carolyn.philpott@uchealth.com</email>
    </contact_backup>
    <investigator>
      <last_name>Carolyn Philpott, PharmD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sarah Schuman-Harlan, PharmD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shaun Keegan, PharmD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christopher Droege, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Molly Droege, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Mueller, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kiranpal Sangha, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brandon Foreman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laura Ngwenya, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cook AM, Hatton-Kolpek J. Augmented Renal Clearance. Pharmacotherapy. 2019 Mar;39(3):346-354. doi: 10.1002/phar.2231. Epub 2019 Mar 11. Review.</citation>
    <PMID>30723936</PMID>
  </reference>
  <reference>
    <citation>Rowe AS, Goodwin H, Brophy GM, Bushwitz J, Castle A, Deen D, Johnson D, Lesch C, Liang N, Potter E, Roels C, Samaan K, Rhoney DH; Neurocritical Care Society Pharmacy Section. Seizure prophylaxis in neurocritical care: a review of evidence-based support. Pharmacotherapy. 2014;34(4):396-409. doi: 10.1002/phar.1374. Epub 2013 Nov 26. Review.</citation>
    <PMID>24277723</PMID>
  </reference>
  <reference>
    <citation>Barletta JF, Mangram AJ, Byrne M, Sucher JF, Hollingworth AK, Ali-Osman FR, Shirah GR, Haley M, Dzandu JK. Identifying augmented renal clearance in trauma patients: Validation of the Augmented Renal Clearance in Trauma Intensive Care scoring system. J Trauma Acute Care Surg. 2017 Apr;82(4):665-671. doi: 10.1097/TA.0000000000001387.</citation>
    <PMID>28129261</PMID>
  </reference>
  <results_reference>
    <citation>Zangbar B, Khalil M, Gruessner A, Joseph B, Friese R, Kulvatunyou N, Wynne J, Latifi R, Rhee P, O'Keeffe T. Levetiracetam Prophylaxis for Post-traumatic Brain Injury Seizures is Ineffective: A Propensity Score Analysis. World J Surg. 2016 Nov;40(11):2667-2672.</citation>
    <PMID>27307089</PMID>
  </results_reference>
  <results_reference>
    <citation>Gabriel WM, Rowe AS. Long-term comparison of GOS-E scores in patients treated with phenytoin or levetiracetam for posttraumatic seizure prophylaxis after traumatic brain injury. Ann Pharmacother. 2014 Nov;48(11):1440-4. doi: 10.1177/1060028014549013. Epub 2014 Aug 28.</citation>
    <PMID>25169249</PMID>
  </results_reference>
  <results_reference>
    <citation>Inaba K, Menaker J, Branco BC, Gooch J, Okoye OT, Herrold J, Scalea TM, Dubose J, Demetriades D. A prospective multicenter comparison of levetiracetam versus phenytoin for early posttraumatic seizure prophylaxis. J Trauma Acute Care Surg. 2013 Mar;74(3):766-71; discussion 771-3. doi: 10.1097/TA.0b013e3182826e84.</citation>
    <PMID>23425733</PMID>
  </results_reference>
  <results_reference>
    <citation>Jones KE, Puccio AM, Harshman KJ, Falcione B, Benedict N, Jankowitz BT, Stippler M, Fischer M, Sauber-Schatz EK, Fabio A, Darby JM, Okonkwo DO. Levetiracetam versus phenytoin for seizure prophylaxis in severe traumatic brain injury. Neurosurg Focus. 2008 Oct;25(4):E3. doi: 10.3171/FOC.2008.25.10.E3.</citation>
    <PMID>18828701</PMID>
  </results_reference>
  <results_reference>
    <citation>Szaflarski JP, Sangha KS, Lindsell CJ, Shutter LA. Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis. Neurocrit Care. 2010 Apr;12(2):165-72. doi: 10.1007/s12028-009-9304-y.</citation>
    <PMID>19898966</PMID>
  </results_reference>
  <results_reference>
    <citation>Ramael S, Daoust A, Otoul C, Toublanc N, Troenaru M, Lu ZS, Stockis A. Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study. Epilepsia. 2006 Jul;47(7):1128-35.</citation>
    <PMID>16886975</PMID>
  </results_reference>
  <results_reference>
    <citation>Steinhoff BJ, Staack AM. Levetiracetam and brivaracetam: a review of evidence from clinical trials and clinical experience. Ther Adv Neurol Disord. 2019 Sep 9;12:1756286419873518. doi: 10.1177/1756286419873518. eCollection 2019. Review.</citation>
    <PMID>31523280</PMID>
  </results_reference>
  <results_reference>
    <citation>Spencer DD, Jacobi J, Juenke JM, Fleck JD, Kays MB. Steady-state pharmacokinetics of intravenous levetiracetam in neurocritical care patients. Pharmacotherapy. 2011 Oct;31(10):934-41. doi: 10.1592/phco.31.10.934.</citation>
    <PMID>21950640</PMID>
  </results_reference>
  <results_reference>
    <citation>Cotta MO, Abdul-Aziz MH, Frey OR, Sime FB, Roberts JA, Roehr AC. What Are the Predictors for Achieving Therapeutic Levetiracetam Serum Concentrations in Adult Neurological Patients? Ther Drug Monit. 2020 Aug;42(4):626-630. doi: 10.1097/FTD.0000000000000731.</citation>
    <PMID>31977751</PMID>
  </results_reference>
  <results_reference>
    <citation>Klein P, Herr D, Pearl PL, Natale J, Levine Z, Nogay C, Sandoval F, Trzcinsky S, Atabaki SM, Tsuchida T, van den Anker J, Soldin SJ, He J, McCarter R. Results of phase II pharmacokinetic study of levetiracetam for prevention of post-traumatic epilepsy. Epilepsy Behav. 2012 Aug;24(4):457-61. doi: 10.1016/j.yebeh.2012.05.011. Epub 2012 Jul 7.</citation>
    <PMID>22771222</PMID>
  </results_reference>
  <results_reference>
    <citation>Uges JW, van Huizen MD, Engelsman J, Wilms EB, Touw DJ, Peeters E, Vecht CJ. Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus. Epilepsia. 2009 Mar;50(3):415-21. doi: 10.1111/j.1528-1167.2008.01889.x. Epub 2008 Nov 17.</citation>
    <PMID>19054418</PMID>
  </results_reference>
  <results_reference>
    <citation>Udy A, Boots R, Senthuran S, Stuart J, Deans R, Lassig-Smith M, Lipman J. Augmented creatinine clearance in traumatic brain injury. Anesth Analg. 2010 Dec;111(6):1505-10. doi: 10.1213/ANE.0b013e3181f7107d. Epub 2010 Nov 3.</citation>
    <PMID>21048095</PMID>
  </results_reference>
  <results_reference>
    <citation>May CC, Arora S, Parli SE, Fraser JF, Bastin MT, Cook AM. Augmented Renal Clearance in Patients with Subarachnoid Hemorrhage. Neurocrit Care. 2015 Dec;23(3):374-9. doi: 10.1007/s12028-015-0127-8.</citation>
    <PMID>25761425</PMID>
  </results_reference>
  <results_reference>
    <citation>Tong X, Patsalos PN. A microdialysis study of the novel antiepileptic drug levetiracetam: extracellular pharmacokinetics and effect on taurine in rat brain. Br J Pharmacol. 2001 Jul;133(6):867-74.</citation>
    <PMID>11454660</PMID>
  </results_reference>
  <results_reference>
    <citation>Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.</citation>
    <PMID>1244564</PMID>
  </results_reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 10, 2020</study_first_submitted>
  <study_first_submitted_qc>April 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>April 7, 2021</last_update_submitted>
  <last_update_submitted_qc>April 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cincinnati</investigator_affiliation>
    <investigator_full_name>Sarah Schuman Harlan</investigator_full_name>
    <investigator_title>Pharmacy Resident, Primary Investigator</investigator_title>
  </responsible_party>
  <keyword>Levetiracetam</keyword>
  <keyword>Seizure Prophylaxis</keyword>
  <keyword>Pharmacokinetic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

